Decreased prevalence and altered clinical phenotype of systemic sclerosis and other autoimmune connective tissue diseases in type 1 and type 2 diabetes: A cross-sectional observational study

Abstract

Introduction:

Evidence has demonstrated that autoimmune diseases tend to coexist at a higher rate than expected, reflecting a common pathogenic pathway. In this study, we investigate the co-occurrence of systemic sclerosis, systemic lupus erythematosus, and Sjogren syndrome in patients with type 1 and type 2 diabetes mellitus.

Methods:

Our data were obtained using the 2019 Healthcare Cost and Utilization Project, and International Classification of Diseases, 10th Revision diagnosis codes were used to identify patients with systemic sclerosis, systemic lupus erythematosus, lupus nephritis, and Sjogren syndrome, as well as patients with type 1 and type 2 diabetes. We utilized Statistical Analysis System 9.4 for all analyses and included designated weight values to produce nationally representative estimates.

Results:

The prevalence of systemic sclerosis among patients with type 1 diabetes mellitus and type 2 diabetes mellitus was significantly lower than that for the non-diabetes mellitus control group (0.0007% vs 0.09%, p-value = 0.0064 and 0.01% vs 0.07%, p-value < 0.0001), respectively. Similarly, there was a significant decrease in the prevalence of systemic sclerosis with lung involvement in patients with type 1 and type 2 diabetes mellitus, with a statically significant difference in type 2 diabetes mellitus versus nondiabetic group (0.001% vs 0.006%, p-value < 0.0001). We noted a similar pattern regarding the prevalence of systemic lupus erythematosus and lupus nephritis in patients with type 1 and 2 diabetes. Similarly, there was a significant decrease in the prevalence of Sjogren syndrome in patients with type 1 diabetes and type 2 diabetes.

Conclusion:

The collected data demonstrates an inverse relation between some autoimmune connective tissue diseases and diabetes. This suggests that these diseases and diabetes mellitus may have different immune pathogenesis. There was also a significantly lower incidence of organ complications such as lupus nephritis and systemic sclerosis lung disease among patients with diabetes, suggesting that diabetes and treatment of diabetes may alter the clinical expression of these disorders.

Keywords

Systemic sclerosis systemic lupus erythematosus Sjogren syndrome diabetes

Get full access to this article

View all access options for this article.

References

Desbois

Cacoub

Systemic sclerosis: an update in 2016. Autoimmun Rev 2016; 15(5): 417–426.

Rigamonti

Shand

Feudjo

, et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006; 55(3): 388–394.

Conrad

Misra

Verbakel

, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 2023; 401(10391): 1878–1890.

Echeverri

Tobón

GJ.

Autoimmune diabetes mellitus (Type 1A). In: Anaya

Shoenfeld

Rojas-Villarraga

, et al. (eds) Autoimmunity: from bench to bedside (Internet). Bogota, Colombia: University of El Rosario Press, 2013: 519–535.

Galicia-Garcia

Benito-Vicente

Jebari

, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 2020; 21(17): 6275.

Velloso

Eizirik

Cnop

Type 2 diabetes mellitus—an autoimmune disease. Nat Rev Endocrinol 2013; 9(12): 750–755.

Triolo

Armstrong

McFann

, et al. Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care 2011; 34(5): 1211–1213.

Tseng

C-C

Chang

S-J

Tsai

W-C

, et al. Reduced incidence of type 1 diabetes and type 2 diabetes in systemic sclerosis: a nationwide cohort study. Joint Bone Spine 2016; 83(3): 307–313.

Blüher

Fasshauer

Tönjes

, et al. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 2005; 113(9): 534–537.

10.

Tai

Yasuda

Xiang

, et al. IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice. Clin Immunol 2011; 139(3): 336–349.

11.

Dziankowska-Bartkowiak

Waszczykowska

Zalewska

, et al. Evaluation of caspase 1 and sFas serum levels in patients with systemic sclerosis: correlation with lung dysfunction, joint and bone involvement. Mediators Inflamm 2003; 12(6): 339–343.

12.

Miyata

Zhang

Chan

JSD

. The rationale and evidence for SGLT2 inhibitors as a treatment for nondiabetic glomerular disease. Glomerular Dis 2021; 1(1): 21–33.

13.

Melichian

Chang

, et al. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-γ. Am J Pathol 2009; 174(2): 519–533.

14.

Wang

Sun

, et al. Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial. RMD Open 2022; 8(2): e002686.

15.

Binder

Maddison

Skinner

, et al. Sjögren’s syndrome: association with type-1 diabetes mellitus. Br J Rheumatol 1989; 28(6): 518–520.

16.

Wang

C-Y

Lai

J-N

Liu

C-H

, et al. Metformin use was associated with reduced risk of incidental Sjögren’s syndrome in patients with type 2 diabetes: a population-based cohort study. Front Med 2022; 8: 796615.

17.

Kim

J-W

Kim

S-M

Park

J-S

, et al. Metformin improves salivary gland inflammation and hypofunction in murine Sjögren’s syndrome. Arthritis Res Ther 2019; 21: 1–11.

18.

Chen

T-H

Lai

T-Y

Wang

Y-H

, et al. Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome. QJM Int J Med 2019; 112(10): 757–762.